Neumora Therapeutics (NMRA) Change in Account Payables (2022 - 2026)

Neumora Therapeutics' Change in Account Payables history runs 5 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Change in Account Payables rose 174.41% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $4.0 million (up 845.62% YoY), while the FY2025 annual figure was $71000.0, down 97.53% from the prior year.
• Change in Account Payables was $1.7 million for Q1 2026 at Neumora Therapeutics, down from $2.8 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $7.0 million in Q2 2023 to a low of -$6.0 million in Q1 2023.
• Historically, Change in Account Payables has averaged $66571.4 across 5 years, with a median of -$252000.0 in 2025.
• The sharpest annual moves came in 2024 and 2025: Change in Account Payables soared 1542.16% in 2024, then plunged 295.24% in 2025.
• A 5-year view of Change in Account Payables shows it stood at -$3.1 million in 2022, then soared by 38.5% to -$1.9 million in 2023, then tumbled by 51.52% to -$2.9 million in 2024, then soared by 197.69% to $2.8 million in 2025, then sank by 40.71% to $1.7 million in 2026.
• The last three Change in Account Payables figures came in at $1.7 million (Q1 2026), $2.8 million (Q4 2025), and -$96000.0 (Q3 2025), per Business Quant data.